drugset / Trial / NCT04327037
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Phase 1
Completed
10 enrolled
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the safety of ex vivo expanded haploidentical natural killer (NK) cells for patients with leukemia.
Timeline
- Start
- 2019-01-02
- Primary completion
- 2021-06-06
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Expanded Haploidentical Natural Killer cells | Cell therapy | 20 cells/kg | Intravenous |
| Subject | Expanded Haploidentical Natural Killer cells | Cell therapy | 50 cells/kg | Intravenous |
| Subject | Expanded Haploidentical Natural Killer cells | Cell therapy | 70 cells/kg | Intravenous |
| Subject | Expanded Haploidentical Natural Killer cells | Cell therapy | 100 cells/kg | Intravenous |
| Background | IL-2 | Protein / enzyme biologic | 1e+06 unknown | Subcutaneous |